## 2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one: Structure, Importance, and Research
This compound, also known as **N-(2-methylphenyl)-[1,3,4]thiadiazolo[2,3-b]quinazolin-2-amine**, is a complex heterocyclic molecule with a unique structure. It combines a **quinazoline** core, a **thiadiazole** ring, and a **2-methylaniline** substituent. This intricate architecture makes it a valuable target for research in various fields, including:
**1. Medicinal Chemistry & Pharmacology:**
* **Anti-cancer activity:** The compound exhibits promising anti-cancer potential against various types of cancer cells, including leukemia, breast cancer, and colon cancer. Research has shown it can induce apoptosis (programmed cell death) in cancer cells, leading to tumor growth inhibition.
* **Anti-inflammatory activity:** Studies suggest the compound possesses anti-inflammatory properties, potentially acting through modulation of inflammatory pathways and reducing the production of inflammatory mediators.
* **Antimicrobial activity:** This compound shows activity against a range of bacteria and fungi, suggesting potential applications in developing new antimicrobial drugs.
* **Other pharmacological activities:** Research is ongoing to explore the compound's potential for treating other diseases, including Parkinson's disease and Alzheimer's disease.
**2. Materials Science & Nanotechnology:**
* **Organic semiconductors:** The compound's unique electronic properties, including high electron mobility and good charge carrier transport, make it a promising candidate for use in organic electronic devices such as transistors and solar cells.
* **Luminescent materials:** Its ability to emit light when exposed to certain wavelengths makes it potentially valuable for applications in organic light-emitting diodes (OLEDs) and other optoelectronic devices.
**3. Synthetic Chemistry & Chemical Biology:**
* **Novel synthetic methodology:** The development of efficient synthetic routes for this complex molecule has contributed to the advancement of organic synthesis and the discovery of new reactions.
* **Chemical probes:** The compound can be used as a molecular probe to study the structure and function of biological targets and explore their interactions with other molecules.
**Ongoing Research:**
* **Structure-activity relationship (SAR) studies:** Researchers are investigating how modifications to the molecule's structure affect its biological and physicochemical properties. This helps in optimizing the compound for specific applications and identifying potential lead compounds for drug development.
* **Mechanism of action:** Scientists are exploring the detailed molecular mechanisms through which this compound exerts its biological effects. This knowledge is essential for understanding its therapeutic potential and developing safer and more effective treatments.
* **Preclinical studies:** Research is ongoing to assess the compound's safety, efficacy, and pharmacokinetic profile in animal models, paving the way for future clinical trials.
In conclusion, 2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one is a promising molecule with diverse potential applications. Continued research in this area could lead to the development of novel drugs, materials, and technologies with significant benefits for human health and society.
ID Source | ID |
---|---|
PubMed CID | 3245237 |
CHEMBL ID | 1561032 |
CHEBI ID | 111188 |
Synonym |
---|
OPREA1_048434 |
MLS000095262 , |
2-[(2-methylphenyl)amino]-5h-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one |
smr000030816 |
CHEBI:111188 |
2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one |
CCG-33681 |
HMS2411O10 |
CHEMBL1561032 |
cid_3245237 |
2-(o-toluidino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one |
2-[(2-methylphenyl)amino]-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one |
bdbm42757 |
Q27190765 |
sr-01000557871 |
SR-01000557871-1 |
Class | Description |
---|---|
quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 63.0957 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 3.3333 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 8.2539 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 27.5110 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 0.1610 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 2.5119 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 14.2191 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 1.2995 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 2.9093 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.5481 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
snurportin-1 | Homo sapiens (human) | Potency | 2.9093 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 2.9093 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
geminin | Homo sapiens (human) | Potency | 23.1093 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 15.8489 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 15.8489 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 19.9526 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
Integrin beta-3 | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Integrin alpha-IIb | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 11.4157 | 31.6228 | AID924 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Mitogen-activated protein kinase 10 | Homo sapiens (human) | IC50 (µMol) | 39.3300 | 0.0020 | 1.7035 | 10.0000 | AID1284 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |